- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03268122
Comparison of Standard Isolation With Targeted Isolation for Preventing Nosocomial Transmission of MRSA and VRE (CONTACT-PILOT)
June 12, 2018 updated by: Todd Rice, Vanderbilt University Medical Center
Comparison of Standard Isolation With Targeted Isolation for Preventing Nosocomial Transmission of MRSA and VRE: A Pilot Clinical Trial
Hospital-acquired infections are common and frequently lead to poor outcomes, including death, in affected patients.
Two common organisms that cause infections in the hospital are methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE).
One strategy used to prevent these infections is contact isolation of hospitalized patients with MRSA and/or VRE.
It is unclear whether contact isolation decreases the rate of infection with MRSA and/or VRE.
The CONTACT-PILOT study is designed to test the hypothesis that contact isolation decreases the rate of infection with MRSA and/or VRE in patients in the intensive care unit (ICU).
The study will enroll all adults in the Medical ICU and will run between September 2017 and April 2018.
During some months, all patients in the Medical ICU patients will be placed in isolation for MRSA or VRE if they have a current infection or colonization with either organism, or a recent history thereof.
During other months, patients will only be placed in isolation for MRSA or VRE if they have an active, highly-transmissible infection with either organism, such as a pneumonia or an open, draining wound.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
CONTACT-PILOT is a single center, pilot, multiple crossover, cluster-randomized trial of contact isolation for MRSA and VRE in the Vanderbilt Medical Intensive Care Unit (MICU) in order to determine if contact isolation reduces the rate of ICU-acquired infection with MRSA and/or VRE.
Specifically, the study will randomly assign the entire MICU to one of two contact isolation strategies for 2 months, and then switch the entire MICU over to the second strategy.
The first strategy is the current practice, also referred to as standard contact isolation, which is to place all patients with MRSA and/or VRE infection or colonization (or a history of either) on contact isolation.
The second strategy is targeted contact isolation, in which patients with MRSA and/or VRE would only be placed on contact isolation if they have an active infection with one (or both) of these organisms with a high risk of transmission, such as an open, draining wound or a pneumonia.
The study will be divided into four alternating 2-month treatment blocks, two for each strategy, with one "run-in" week at the start of each treatment block in order to transition between the two treatment strategies, for a total study duration of 8 months.
The interventions will occur between September 1, 2017 and April 30, 2018.
All adult MICU patients will be enrolled in the study.
The primary outcome will be the rate of new ICU-acquired MRSA and VRE infections.
Data analysis will be performed using a pre-specified data analysis plan.
This study is being performed as a preliminary study to evaluate the feasibility and safety of the study plan.
Study Type
Interventional
Enrollment (Actual)
1974
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37209
- Vanderbilt University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- All adult patients admitted to the study ICU, the Vanderbilt University Medical Center Medical Intensive Care Unit, during an active enrollment period
Exclusion Criteria:
- Age less than 18 years old
- Patients admitted during a run-in period
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard Contact Isolation
Patients in the standard contact isolation arm will be under the standard contact isolation strategy during the entire time they are physically located in the Medical ICU.
|
With regards to MRSA and VRE, the wearing of gowns and gloves will be required for all staff entering a patient room if the patent has an infection or colonization with MRSA or VRE or a recent history (within 90 days) of either
Other Names:
|
Active Comparator: Targeted Contact Isolation
Patients in the targeted contact isolation arm will be under the targeted contact isolation strategy during the entire time they are physically located in the Medical ICU.
|
With regards to MRSA and VRE, the wearing of gowns and gloves will be required for all staff entering a patient room if the patient has an active, highly-transmissible infection with MRSA and/or VRE. A highly-transmissible infection is defined as one with uncontained secretions or excretions (diarrhea, vomiting, or open draining wounds) or pneumonia.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite rate of ICU-acquired MRSA or VRE infections
Time Frame: 48 hours after enrollment to 48 hours after study ICU discharge, censored at 28 days after enrollment
|
The primary endpoint is defined as an MRSA or VRE infection in a patient not currently diagnosed with or being treated for that infection at least 48 hours after admission to the study ICU and while the patient either remains in the study ICU or is within 48 hours of discharge or transfer from the study ICU, truncated at day 28 after enrollment.
The composite rate will be reported in infections per 1000 patient-days.
|
48 hours after enrollment to 48 hours after study ICU discharge, censored at 28 days after enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of ICU-acquired MRSA infection
Time Frame: 48 hours after enrollment to 48 hours after study ICU discharge, censored at 28 days after enrollment
|
An MRSA infection in a patient not currently diagnosed with or being treated for that infection at least 48 hours after admission to the study ICU and while the patient either remains in the study ICU or is within 48 hours of discharge or transfer from the study ICU, truncated at day 28 after enrollment.
The rate will be reported in infections per 1000 patient-days.
|
48 hours after enrollment to 48 hours after study ICU discharge, censored at 28 days after enrollment
|
Rate of ICU-acquired VRE infection
Time Frame: 48 hours after enrollment to 48 hours after study ICU discharge, censored at 28 days after enrollment
|
A VRE infection in a patient not currently diagnosed with or being treated for that infection at least 48 hours after admission to the study ICU and while the patient either remains in the study ICU or is within 48 hours of discharge or transfer from the study ICU, truncated at day 28 after enrollment.
The rate will be reported in infections per 1000 patient-days.
|
48 hours after enrollment to 48 hours after study ICU discharge, censored at 28 days after enrollment
|
Rate of ICU-acquired MRSA bacteremia
Time Frame: 48 hours after enrollment to 48 hours after study ICU discharge, censored at 28 days after enrollment
|
A positive clinical blood culture for MRSA in a patient not currently diagnosed with or being treated with that infection at least 48 hours after admission to the study ICU and while the patient either remains in the study ICU or is within 48 hours of discharge or transfer from the study ICU, truncated at day 28 after enrollment.
The rate will be reported in infections per 1000 patient-days.
|
48 hours after enrollment to 48 hours after study ICU discharge, censored at 28 days after enrollment
|
Rate of ICU-acquired VRE bacteremia
Time Frame: 48 hours after enrollment to 48 hours after study ICU discharge, censored at 28 days after enrollment
|
A positive clinical blood culture for VRE in a patient not currently diagnosed with or being treated for that infection at least 48 hours after admission to the study ICU and while the patient either remains in the study ICU or is within 48 hours of discharge or transfer from the study ICU, truncated at day 28 after enrollment.
The rate will be reported in infections per 1000 patient-days.
|
48 hours after enrollment to 48 hours after study ICU discharge, censored at 28 days after enrollment
|
Composite rate of ICU-acquired MRSA or VRE bacteremia
Time Frame: 48 hours after enrollment to 48 hours after study ICU discharge, censored at 28 days after enrollment
|
A clinical blood culture positive for either MRSA or VRE in a patient not currently diagnosed with or being treated for that infection at least 48 hours after admission to the study ICU and while the patient either remains in the study ICU or is within 48 hours of discharge or transfer from the study ICU, truncated at day 28 after enrollment.
The composite rate will be reported in infections per 1000 patient-days.
|
48 hours after enrollment to 48 hours after study ICU discharge, censored at 28 days after enrollment
|
Composite rate of hospital-acquired MRSA or VRE infection
Time Frame: 48 hours after enrollment to 48 hours after study hospital discharge, truncated at 28 days after enrollment
|
An MRSA or VRE infection in a patient not currently diagnosed with or being treated for that infection at least 48 hours after admission to the study ICU and while the patient either remains admitted to the study hospital or is within 48 hours of discharge or transfer from the study hospital, truncated at day 28 after enrollment.
The composite rate will be reported in infections per 1000 patient-days.
|
48 hours after enrollment to 48 hours after study hospital discharge, truncated at 28 days after enrollment
|
Composite rate of hospital-acquired CLABSI, CAUTI, BSI, Clostridium difficile infection, and VAP.
Time Frame: 48 hours after enrollment to 48 hours after study ICU discharge, truncated at day 28 after enrollment (except for Clostridium difficile infections, which are truncated at the time of study ICU discharge)
|
Composite rate of certain healthcare-associated infections: central line-associated bloodstream infection (CLABSI), catheter-associated urinary tract infection (CAUTI), bloodstream infection (BSI), Clostridium difficile infection, and ventilator-associated pneumonia (VAP) in patients not currently diagnosed with or being treated for those infections, truncated at day 28 after enrollment.
|
48 hours after enrollment to 48 hours after study ICU discharge, truncated at day 28 after enrollment (except for Clostridium difficile infections, which are truncated at the time of study ICU discharge)
|
28-day mortality
Time Frame: Date of enrollment until 28 days after enrollment
|
All-cause mortality up until 28 days after enrollment, censored at hospital discharge
|
Date of enrollment until 28 days after enrollment
|
In-hospital mortality
Time Frame: Date of enrollment until hospital discharge, censored at 28 days after enrollment
|
All-cause death while admitted to the study hospital, truncated 28 days after enrollment
|
Date of enrollment until hospital discharge, censored at 28 days after enrollment
|
ICU mortality
Time Frame: Date of enrollment until study ICU discharge, censored at 28 days after enrollment
|
All-cause death while admitted to the study ICU, truncated 28 days after enrollment
|
Date of enrollment until study ICU discharge, censored at 28 days after enrollment
|
ICU length of stay
Time Frame: Study enrollment until study ICU discharge, truncated at 28 days after enrollment
|
Length of Stay in the ICU
|
Study enrollment until study ICU discharge, truncated at 28 days after enrollment
|
Hospital length of stay
Time Frame: Study enrollment until study hospital discharge, truncated at 28 days after enrollment
|
Length of Stay in the Hospital
|
Study enrollment until study hospital discharge, truncated at 28 days after enrollment
|
Proportion compliant with hand hygiene
Time Frame: Up to 8 months
|
Compliance by staff members with hand hygiene will be defined as using alcohol-based foam and/or soap and water immediately before entering a patient room and immediately after exiting a patient room, unless the patient specifically requires soap and water to be utilized after exiting their patient room (e.g. a patient with Clostridium difficile infection), in which case compliance after exiting that patient room would only be achieved by handwashing with soap and water.
|
Up to 8 months
|
Proportion compliant with contact isolation
Time Frame: Up to 8 months
|
Compliance with contact isolation precautions by staff members will be defined as donning gown and gloves immediately prior to entering a patient room and removal of both of these items immediately before exiting a patient room.
|
Up to 8 months
|
Estimated cost of gowns and gloves
Time Frame: Up to 8 months
|
This outcome will be calculated from the rate of gowns and gloves delivered to the ICU and the cost of gowns and gloves immediately prior to the start of the study.
|
Up to 8 months
|
Rate of gowns delivered to ICU per patient-day
Time Frame: Up to 8 months
|
Number of gowns divided by patient ICU days
|
Up to 8 months
|
Rate of gloves delivered to ICU per patient-day
Time Frame: Up to 8 months
|
Number of gloves divided by patient ICU days
|
Up to 8 months
|
Adverse events (composite of falls, medication administration errors, and pressure ulcers)
Time Frame: Study enrollment until study ICU discharge, truncated at 28 days after enrollment
|
Composite of falls, medication administration errors, and pressure ulcers, as defined in their respective outcomes
|
Study enrollment until study ICU discharge, truncated at 28 days after enrollment
|
Falls
Time Frame: Study enrollment until study ICU discharge, truncated at 28 days after enrollment
|
Documented patient fall, regardless of degree of injury sustained
|
Study enrollment until study ICU discharge, truncated at 28 days after enrollment
|
Medication administration errors
Time Frame: Study enrollment until study ICU discharge, truncated at 28 days after enrollment
|
Documented error in administration of medications to patients, regardless of any adverse effect on the patient
|
Study enrollment until study ICU discharge, truncated at 28 days after enrollment
|
Pressure ulcers
Time Frame: Study enrollment until study ICU discharge, truncated at 28 days after enrollment
|
Documented new pressure ulcer
|
Study enrollment until study ICU discharge, truncated at 28 days after enrollment
|
New MRSA colonization
Time Frame: Study enrollment until study ICU discharge, truncated at 28 days after enrollment
|
Patient with admission surveillance culture negative for MRSA but with discharge surveillance culture positive for MRSA (collected during the final 4 months of the study).
|
Study enrollment until study ICU discharge, truncated at 28 days after enrollment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Todd W Rice, MD, MSc, Vanderbilt University Medical Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Huskins WC, Huckabee CM, O'Grady NP, Murray P, Kopetskie H, Zimmer L, Walker ME, Sinkowitz-Cochran RL, Jernigan JA, Samore M, Wallace D, Goldmann DA; STAR*ICU Trial Investigators. Intervention to reduce transmission of resistant bacteria in intensive care. N Engl J Med. 2011 Apr 14;364(15):1407-18. doi: 10.1056/NEJMoa1000373.
- Harris AD, Pineles L, Belton B, Johnson JK, Shardell M, Loeb M, Newhouse R, Dembry L, Braun B, Perencevich EN, Hall KK, Morgan DJ; Benefits of Universal Glove and Gown (BUGG) Investigators, Shahryar SK, Price CS, Gadbaw JJ, Drees M, Kett DH, Munoz-Price LS, Jacob JT, Herwaldt LA, Sulis CA, Yokoe DS, Maragakis L, Lissauer ME, Zervos MJ, Warren DK, Carver RL, Anderson DJ, Calfee DP, Bowling JE, Safdar N. Universal glove and gown use and acquisition of antibiotic-resistant bacteria in the ICU: a randomized trial. JAMA. 2013 Oct 16;310(15):1571-80. doi: 10.1001/jama.2013.277815.
- Huang SS, Septimus E, Kleinman K, Moody J, Hickok J, Avery TR, Lankiewicz J, Gombosev A, Terpstra L, Hartford F, Hayden MK, Jernigan JA, Weinstein RA, Fraser VJ, Haffenreffer K, Cui E, Kaganov RE, Lolans K, Perlin JB, Platt R; CDC Prevention Epicenters Program; AHRQ DECIDE Network and Healthcare-Associated Infections Program. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med. 2013 Jun 13;368(24):2255-65. doi: 10.1056/NEJMoa1207290. Epub 2013 May 29. Erratum In: N Engl J Med. 2013 Aug 8;369(6):587. N Engl J Med. 2014 Feb 27;370(9):886.
- Morgan DJ, Murthy R, Munoz-Price LS, Barnden M, Camins BC, Johnston BL, Rubin Z, Sullivan KV, Shane AL, Dellinger EP, Rupp ME, Bearman G. Reconsidering contact precautions for endemic methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol. 2015 Oct;36(10):1163-72. doi: 10.1017/ice.2015.156. Epub 2015 Jul 3.
- Derde LPG, Cooper BS, Goossens H, Malhotra-Kumar S, Willems RJL, Gniadkowski M, Hryniewicz W, Empel J, Dautzenberg MJD, Annane D, Aragao I, Chalfine A, Dumpis U, Esteves F, Giamarellou H, Muzlovic I, Nardi G, Petrikkos GL, Tomic V, Marti AT, Stammet P, Brun-Buisson C, Bonten MJM; MOSAR WP3 Study Team. Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. Lancet Infect Dis. 2014 Jan;14(1):31-39. doi: 10.1016/S1473-3099(13)70295-0. Epub 2013 Oct 23. Erratum In: Lancet Infect Dis. 2014 Jan;14(1):11.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2017
Primary Completion (Actual)
May 30, 2018
Study Completion (Actual)
May 30, 2018
Study Registration Dates
First Submitted
August 9, 2017
First Submitted That Met QC Criteria
August 28, 2017
First Posted (Actual)
August 31, 2017
Study Record Updates
Last Update Posted (Actual)
June 14, 2018
Last Update Submitted That Met QC Criteria
June 12, 2018
Last Verified
June 1, 2018
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 161137
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on VRE Infection
-
University Hospital of CologneUniversitätsklinikum Hamburg-Eppendorf; University of Freiburg; University Hospital...UnknownAntibiotic Resistant Infection | VRE InfectionGermany
-
Hvidovre University HospitalChr HansenCompleted
-
Hunter Holmes Mcguire Veteran Affairs Medical CenterJohns Hopkins University; Washington University School of Medicine; Weill Medical... and other collaboratorsCompletedMRSA Infection | MRSA Colonization | VRE Infection | VRE Colonization | Nosocomial Bacteremia | Nosocomial FungemiaUnited States
-
Hunter Holmes Mcguire Veteran Affairs Medical CenterCenters for Disease Control and Prevention; Sage Products, Inc.UnknownMRSA Infection | MRSA Colonization | VRE Infection | VRE Colonization | Nosocomial BacteremiaUnited States
-
Hacettepe UniversityThe Scientific and Technological Research Council of TurkeyCompletedMRSA Colonization | VRE ColonizationTurkey
-
University of PittsburghTerminatedVRE ColonizationUnited States
-
University Hospital of CologneCharite University, Berlin, Germany; University Hospital Tuebingen; University... and other collaboratorsCompletedClostridium Difficile Infection | Nosocomial Infection | VRE Infection | MRGN BacteriaGermany
-
University of CologneUniversity Hospital Tuebingen; University Hospital Freiburg; Universitätsklinikum... and other collaboratorsUnknownCancer | Vancomycin (Glycopeptide) Resistant Enterococcus (VRE)
-
University of PennsylvaniaNot yet recruitingEnterobacteriaceae Infections | Methicillin-resistant Staphylococcus Aureus | Pseudomonas Aeruginosa | VRE Infection | Multidrug Resistant Bacterial InfectionUnited States
-
Chuncheon Sacred Heart HospitalSeverance Hospital; National Institute of Health, KoreaRecruitingCarbapenem-Resistant Enterobacteriaceae | Vancomycin (Glycopeptide) Resistant Enterococcus (VRE)Korea, Republic of
Clinical Trials on Standard Contact Isolation
-
Seoul National University HospitalKeimyung University Dongsan Medical CenterCompletedAtrial FibrillationKorea, Republic of
-
Queen Mary University of LondonCompletedAtrial Fibrillation | Atrial Fibrillation Ablation | Pulmonary Vein IsolationUnited Kingdom
-
University of ZurichTerminatedSleep Apnea, Obstructive | Atrial Fibrillation | Atrial Premature ComplexesSwitzerland
-
Korea University Anam HospitalBiosense Webster, Inc.UnknownPersistent Atrial FibrillationKorea, Republic of
-
Northwestern MedicineUnknownElectrocardiogram Electrode Site ReactionUnited States
-
Dignity Health Medical FoundationBeth Israel Deaconess Medical Center; Brigham and Women's Hospital; St. Luke's... and other collaboratorsActive, not recruitingPersistent Atrial FibrillationUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphoid System Neoplasm | Hereditary Malignant NeoplasmUnited States
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSepsis | Septic Shock | Hematologic Malignancy | Tumor | Allogeneic Stem Cell Transplantation
-
Centers for Disease Control and PreventionHealth Resources and Services Administration (HRSA)CompletedPrimary Care Appointment KeepingUnited States
-
Baylor College of MedicineCompletedGeneralized Anxiety Disorder | Panic Disorder | Separation Anxiety | Panic Attacks | Social Anxiety Disorder of Childhood | Obsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in Adolescence | Panic With AgoraphobiaUnited States